Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY EVALUATING THE EFFECT OF THE CYTOCHROME P450 3A INHIBITOR ITRACONAZOLE ON DNL151 IN HEALTHY SUBJECTS

X
Trial Profile

A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY EVALUATING THE EFFECT OF THE CYTOCHROME P450 3A INHIBITOR ITRACONAZOLE ON DNL151 IN HEALTHY SUBJECTS

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL-151 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Denali Therapeutics Inc
  • Most Recent Events

    • 06 Aug 2020 According to a Denali Therapeutics media release, this trial is anticipated to complete in 2020.
    • 06 Aug 2020 According to a Denali Therapeutics media release, the company has competed dosing of 162 healthy volunteers in this study and is completing further dose escalation cohorts to define the full therapeutic window of the molecule.
    • 02 Apr 2020 According to a Denali Therapeutics media release, Denali is analyzing available data from this trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top